ישראל - עברית - Ministry of Health

rafa laboratories ltd - alprazolam 0.25 mg - tablets - alprazolam - for the management of anxiety and anxiety associated with depression.treatment of panic disorders with or without phobic avodance.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - alprazolam 1 mg - tablets - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - alprazolam 0.5 mg - tablets - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - buprenorphine as hydrochloride 2 mg - tablets sublingual - buprenorphine - substitution treatment for opioid dependence within a framework of medical, social and psychological treatment.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - betahistine hydrochloride 16 mg - tablets - betahistine - meniere`s syndrome. symptomatic treatment of peripheral vertigo.

ישראל - עברית - Ministry of Health

a.m.i. technologies, ltd. - רופא - ג'ל להזרקה לילידים למניעת חזרה של שתן מהשלפוחית לכליה.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - metolazone 5 mg - tablets - metolazone - for the treatment of salt and water retention including: edema accompanying congestive heart failure, edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. for hypertension, alone or in combination with other antihypertensive drugs of a different class.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 750 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 1000 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n